EL7.AI
StocksMediumUpdated•Originally published 16 July 2026•Updated 17 July 2026•
2 min read

Eli Lilly Boosts Psychedelics Bet to $3.8B with Beckley Psytech Deal

Key Facts

1Eli Lilly acquired psychedelics maker Atai Beckley for $2.8 billion.
2The acquisition aims to develop a DMT-like drug for treating depression.

In a move reflecting the growing shift of Big Pharma toward innovative psychiatric treatments, Eli Lilly has announced its entry into the psychedelics market by acquiring assets from Oxford-based Beckley Psytech. According to reports, the total deal value could reach up to $3.8 billion, aiming to bolster the company's mental health pipeline. The acquisition specifically targets the development of BPL-003, a nasal spray based on the 5-MeO-DMT compound designed for treatment-resistant depression.

This strategic maneuver comes as the biotech sector sees surging interest in psychedelic therapies, fueled by the commercial validation of treatments like Johnson & Johnson's Spravato. In comparison to peers, Eli Lilly is positioning itself to compete with firms such as Compass Pathways, which is also developing psilocybin-based therapies. Per market data, LLY shares have been trading at premium levels, reflecting investor confidence in the company's expansion beyond its dominant obesity and diabetes franchise.

Regarding market performance, LLY stock stood at $1170.54 at close July 16, 2026. Traders are now closely watching for Phase II clinical trial data for the BPL-003 candidate, especially as the market awaits the U.S. Monetary Policy Report on July 10, 2026, which could influence risk appetite and capital costs across the high-growth biotech sector.